• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Aileron Therapeutics Inc (NQ: ALRN )

    3.310 -0.260 (-7.28%)
    Streaming Delayed Price Updated: 3:59 PM EST, Nov 14, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Aileron Therapeutics Inc

    Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
    From Aileron Therapeutics, Inc.
    Via GlobeNewswire
    Aileron Therapeutics to Present at Two Upcoming Investor Conferences
    From Aileron Therapeutics, Inc.
    Via GlobeNewswire
    BioMedNewsBreaks — Aileron Therapeutics Inc. (NASDAQ: ALRN) Closes Underwritten Registered Direct Offering
    Via Investor Brand Network
    Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
    Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering 
    From Aileron Therapeutics, Inc.
    Via GlobeNewswire
    Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
    Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering 
    From Aileron Therapeutics, Inc.
    Via GlobeNewswire
    Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
    From Aileron Therapeutics, Inc.
    Via GlobeNewswire
    Aileron Therapeutics Inc. (NASDAQ: ALRN) Leading the Way in Thursday Trading Based on Percentage Gain
    Via Investor Brand Network
    Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From Aileron Therapeutics, Inc.
    Via GlobeNewswire
    Aileron Therapeutics Announces CEO Transition
    From Aileron Therapeutics, Inc.
    Via GlobeNewswire
    Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
    Topline results from Phase 1b study of LTI-03, Aileron’s novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected in the second quarter of 2024 
    From Aileron Therapeutics, Inc.
    Via GlobeNewswire
    Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
    Panel discussion will highlight LTI-03, Aileron’s novel Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis 
    From Aileron Therapeutics, Inc.
    Via GlobeNewswire
    Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives
    From Aileron Therapeutics, Inc.
    Via GlobeNewswire
    Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements
    From Aileron Therapeutics, Inc.
    Via GlobeNewswire
    Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split
    Common Stock Will Begin Trading on Split-Adjusted Basis on November 11, 2022 
    From Aileron Therapeutics, Inc.
    Via GlobeNewswire
    Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
    From Aileron Therapeutics, Inc.
    Via GlobeNewswire
    Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference
    From Aileron Therapeutics, Inc.
    Via GlobeNewswire
    Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022
    From Aileron Therapeutics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.